We are still figuring out the side effects of GLP-1 weight-loss drugs
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Research presented at an aging meeting in Boston found that overweight and diabetic people taking GLP-1 drugs have a biological age about two to three years younger than similar people on a placebo, according to Eli Lilly and Novo Nordisk, which make the drugs. GLP-1 agonists are already approved for diabetes, chronic kidney disease and obesity and are being studied for substance-use disorders, neurodegenerative disease and cancer, while unexplained side effects continue to emerge. A recent Gallup poll found 11% of Americans now take a GLP-1 drug for weight loss, up from 3% in 2024.
Continue in the app — vote & join in ➔Source: MIT Technology Review · via ahirlevel.hu